‘Holy Grail’ of Oral Insulin Gives Way to Other Tablets at Novo
- Company sees oral semaglutide as potential breakthrough
- Novo looking for ‘more shots on goal’ with R&D spending
This article is for subscribers only.
More than 30 years after diabetics began injecting themselves with the modern form of insulin, treatments in a pill seem as elusive as ever.
Delivery of the hormone in a tablet is still considered the “holy grail,” according to Mads Krogsgaard Thomsen, the chief science officer of Novo Nordisk A/S. Yet Novo, the world’s largest maker of insulin, is reviewing its efforts to determine whether the product can be commercially viable, and how much investment would be needed.